ArticleTheranostics2021
PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Protein arginine methyltransferases as metabolic regulators: many roles beyond cancer.Science China. Life sciences · 2026Review
- PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.Leukemia · 2026Article
- Selective Targeting of Protein Arginine Methyltransferase 1 (PRMT1) Mutant Activity by a Small Molecule Activation Strategy.ACS chemical biology · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Exercise preconditioning prevents immobilization-induced skeletal muscle atrophy by activating Prmt1-p38/ATF2-Sesn1 signaling axis in C57BL/6J mice.Sports medicine and health science · 2026Article
- Expression and Significance of Protein Arginine Methyltransferase 1 in the Serum of Patients with Diabetes Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- PRMT1 promotes immune escape in hepatocellular carcinoma by regulating arginine methylation modification of MYC protein.Epigenetics · 2025Article
- Identification of KRBA2 as a probable prognostic biomarker correlated with immune infiltration in kidney clear cell carcinoma.Current urology · 2025Article
- Regulators of Cancer Progression: Succinylation.Cancers · 2025Review
- Overexpression of CircularInternational journal of molecular sciences · 2025Article
- PRMT1-Mediated SWI/SNF Complex Recruitment via SMARCC1 Drives IGF2BP2 Transcription to Enhance Carboplatin Resistance in Head and Neck Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Lipocalin-2 induced LDHA expression promotes vascular remodelling in pulmonary hypertension.Cell proliferation · 2024Article
- Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1.Journal of medicinal chemistry · 2024Review
- PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma.Nature communications · 2024Article
- Bioprinted research models of urological malignancy.Exploration (Beijing, China) · 2024Review
- Identification of a signature of histone modifiers in kidney renal clear cell carcinoma.Aging · 2024Article
- PRMT1 in human neoplasm: cancer biology and potential therapeutic target.Cell communication and signaling : CCS · 2024Review
- Prmt1-mediated histone H4R3me2a methylation regulates the proliferation, migration and invasion of laryngeal cancer cells by affecting the expression level of NCOA5.Frontiers in oncology · 2024Article
- Article
- Critical Roles of Protein Arginine Methylation in the Central Nervous System.Molecular neurobiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 1 country.
Jianfeng WangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Chen WangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Pan XuDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Xiao LiDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Yongning LuZhongshan hospital Fudan University, 180 Fenglin road, Shanghai 200032, China.
Di JinDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Xiaomao YinDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Hao JiangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Jing HuangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Huan XiongDepartment of Chemistry, College of Sciences, Shanghai University, 99 Shangda Road, Shanghai 200444, China.
Fei YeCollege of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310023, China.
Jia JinCollege of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310023, China.
Yu ChenDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Yiqian XiePerkinElmer Management (Shanghai) Co. Ltd, 1670 Zhangheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China.
Zhifeng ChenDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Hong DingDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Hao ZhangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Rongfeng LiuIn vitro Biology, Shanghai ChemPartner Life Science Co., Ltd., #5 Building, 998 Halei Road, Shanghai 201203, China.
Hualiang JiangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Kaixian ChenDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Zhiyi YaoCollege of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai 210032, China.
Cheng LuoDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Yiran HuangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Yuanyuan ZhangDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Jin ZhangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CNRenji Hospital · CNUniversity of Chinese Academy of Sciences · CNShanghai Institute of Technology · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBiomarkers, TumorCarcinogenesisCarcinoma, Renal CellCell Cycle CheckpointsCell LineCell Line, TumorCell ProliferationEpigenesis, GeneticFemaleG1 PhaseGene Expression Regulation, NeoplasticHEK293 CellsHumansKidney NeoplasmsLipocalin-2Biomarkers, TumorLipocalin-2PRMT1 protein, humanProtein-Arginine N-MethyltransferasesRepressor ProteinsSunitinibclear cell renal cell carcinomalipocalin2 (LCN2)protein arginine methyltransferase 1sunitinibtherapeutic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.